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Immunodeficient mice reconstituted with human immune tissues and cells (humanized 
mice) are relevant and robust models for the study of HIV-1 infection, immunopatho-
genesis, and therapy. In this study, we performed a comprehensive comparison of 
human immune reconstitution and HIV-1 infection, immunopathogenesis and therapy 
between immunodeficient NOD/Rag2−/−/γ −/−c  (NRG) mice transplanted with human 
HSCs (NRG-hu HSC) and mice transplanted with HSCs and thymus fragments (NRG-hu 
Thy/HSC) from the same donors. We found that similar human lymphoid and myeloid 
lineages were reconstituted in NRG-hu HSC and NRG-hu Thy/HSC mice, with human 
T cells more predominantly reconstituted in NRG-hu Thy/HSC mice, while NRG-hu HSC 
mice supported more human B cells and myeloid cells reconstitution. HIV-1 replicated 
similarly and induced similar T  cell depletion, immune activation, and dysfunction in 
NRG-hu HSC and NRG-hu Thy/HSC mice. Moreover, combined antiretroviral therapy 
(cART) inhibited HIV-1 replication efficiently with similar persistent HIV-1 reservoirs in 
both models. Finally, we found that blocking type-I interferon signaling under cART treat-
ment transiently activated HIV-1 reservoirs, enhanced T cell recovery and reduced HIV-1 
reservoirs in both HIV-1 infected NRG-hu HSC and NRG-hu Thy/HSC mice. In summary, 
we report that NRG-hu Thy/HSC and NRG-hu HSC mice support similar HIV-1 infection 
and similar HIV-1 immunopathology; and HIV-1 replication responds similarly to cART 
and IFNAR blockade therapies. The NRG-hu HSC mouse model reconstituted with 
human HSC only is sufficient for the study of HIV-1 infection, pathogenesis, and therapy.
Keywords: humanized mice, nrg-hu hsc, nrg-hu Thy/hsc, hiV-1 replication, hiV-1 immunopathology, 
combined antiretroviral therapy, hiV-1 immune therapy
inTrODUcTiOn
Human immunodeficiency virus type 1 (HIV-1) infects and progressively depletes CD4+ T cells, 
causing acquired immune deficiency syndrome (AIDS). Approximately 70 million people have been 
infected with HIV-1, and half of them have died of HIV/AIDS-related causes (1). The development 
of combined antiretroviral therapy (cART), which can efficiently suppress viral replication, has 
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significantly improved survival and life quality of HIV-1-infected 
patients who can both access and tolerate cART (2). However, 
cART is not curative and must be continued for life (3, 4). 
Moreover, lifelong treatment is associated with significant side 
effects and non-AIDS-related “end-organ disease” (5). Thus, there 
is a great need for the development of novel therapies that can 
both control the epidemic and cure those individuals who have 
already been infected with HIV-1.
Understanding how HIV-1 infection leads to immunodefi-
ciency is key for the development of new treatments. After more 
than 30 years of research, the precise mechanism by which HIV-1 
infection causes AIDS development is still poorly understood, 
mainly due to the lack of robust small animal models. The recent 
development of humanized mice with functional human immune 
systems offer a relevant and robust model for the study of 
HIV-1 infection, replication, pathogenesis, and therapies (6–8). 
Humanized mice were constructed by transplantation of human 
CD34+ hematopoietic stem cells and/or implantation of human 
thymus tissue into immunodeficient mice, such as the NOD-
scid γc−/− (NSG) mice and NOD-Rag2−/−γc−/− (NRG) mice (9). 
Two major humanized mouse models, the NRG-hu HSC model 
and the hu-BLT model, are widely used for HIV-1 studies. The 
NRG-hu HSC model involves preconditioning neonate immu-
nodeficient mice with radiation and then injecting them with 
human CD34+ HSCs (10–13). In the hu-BLT model, implantation 
of human thymus tissue under the kidney capsule is combined 
with HSCs infusion into irradiated adult immunodeficient mice 
(14, 15). We and others have reported that all the major human 
lymphoid lineage including T cell, B cell, and innate immune cells 
including NK  cell, monocytes, myeloid dendritic cells (mDC), 
and plasmacytoid dendritic cells (pDC) are developed in both 
NRG-hu HSC mice and hu-BLT mice (10–20).
Both NRG-hu HSC and hu-BLT models can develop signifi-
cant levels of innate and adaptive immune responses (21–25) and 
can be infected by HIV-1 (7, 26–28). HIV-1 infection leads to 
progressive CD4+ T cell depletion in both peripheral blood and 
lymphoid tissues (8). Moreover, like in humans, HIV-1 infection 
also leads to T cell activation and exhaustion in both NRG-hu 
HSC and hu-BLT mice (29–31). HIV-1 infection can be treated 
with the antiretroviral drugs that are used in infected humans 
(32–36). Also like in humans, antiretroviral treatment of HIV-1 
infection results in systemic recovery of CD4 T cells in human-
ized mice. In addition, both mouse models are used for testing 
the effectiveness of immunotherapy to inhibit HIV-1 replication, 
reverse HIV-1 induced immunopathology and control HIV-1 
reservoir (25, 29, 30, 34, 37–39).
The advantage of the NRG-hu HSC model is that the procedure 
to construct the mice is simple, only involving pre-irradiating 
the neonate immunodeficient mice followed by injecting 
human CD34+ HSCs (10, 11, 13). To generate hu-BLT mice, a 
time consuming and technically difficult surgery procedure 
is needed to implant the human thymus tissue into the kidney 
capsule of the mice (14, 15). Another major difference between 
these two models is that in NRG-hu HSC mouse, the human 
T  cells are produced in the mouse thymus and presumed to 
be educated in the context of mouse major histocompatibility 
complex (MHC) (10–13). In hu-BLT mice, human T  cells can 
develop in the presence of human thymic epithelium, resulting 
in human MCH-restricted T  cells (14, 15, 40). Thus, although 
both models are versatile tools for HIV-1 study, parallelly study to 
compare the human immune reconstitution, HIV-1 replication, 
immunopathology, and responses to therapy in both models 
will help to guide researchers how to balance and decide which 
system to use. In this study, we performed a comprehensive 
parallel comparison of human immune reconstitution and HIV-1 
replication, immunopathogenesis and therapy between newborn 
immunodeficient mice transplanted with HSCs (NRG-hu HSC) 
and 6- to 8-week-old adult mice transplanted with HSCs and 
thymus (NRG-hu Thy/HSC) from same human donors into same 
background of immunodeficient mice. We report that both 
NRG-hu HSC and NRG-hu Thy/HSC mice support significant 
levels of human immune reconstitution and comparable levels 
of HIV-1 replication, immunopathology, and responses to cART 
and immune therapy.
MaTerials anD MeThODs
construction of humanized Mice
NRG (NOD-Rag2−/−γc−/−) mice were obtained from the Jackson 
Laboratory. Human fetal liver and thymus (gestational age 
of 16–20  weeks) were obtained from medically or elective 
indicated termination of pregnancy through a non-profit inter-
mediary working with outpatient clinics (Advanced Bioscience 
Resources, Alameda, CA, USA). Written informed consent of 
the maternal donors is obtained in all cases, under regulation 
governing the clinic. NRG-hu HSC mice were generated by 
intrahepatic injection of new born (1–5  days old) NRG mice 
(irradiated at 200 cGy from a 137Cs gamma radiation source) 
with 3 × 105 human fetal liver derived CD34+ HSCs as previ-
ously reported (41). To generate NRG-hu Thy/HSC mice, 6- to 
8-week-old NRG mice were sub-lethally irradiated (250  cGy) 
and anesthetized, and ~1-mm3 fragments of human fetal thymus 
fragments were implanted under the kidney capsule. 5 ×  105 
CD34+ HSCs purified from fetal liver of the same donor were 
injected i.v. within 3  h. All mice were housed and bred in a 
specific pathogen-free environment. All animal studies were 
approved by the University of North Carolina Institutional 
Animal Care and Use Committee.
antibodies and Flow cytometry
Antibodies to CD45 (HI30), CD4 (RPA-T4), CD8 (HIT8a), 
CD56 (5.1h11), CD123 (6H6), CD14 (63D3), CD11c (3.9), 
CD45RA (HI100), CCR7 (G043H7), CD10 (HI10a), IL-2 (MQ1-
17H12), IFN-γ (4S.B3), HLA-DR (L243), CD38 (HIT2), and 
PD-1 (EH12.2H7) were purchased from BioLegend. Antibodies 
to CD3 (7D6), CD19 (6D5), mouse CD45 (30-F11), and LIVE/
DEAD Fixable Yellow Dead Cell Stain Kit were purchased from 
Invitrogen. Antibody to HIV-1 p24 (KC57) were purchased from 
Beckman Coulter.
Total lymphocytes were isolated prepared from peripheral 
blood, spleen, bone marrow (BM), and mesenteric lymph nodes 
(mLNs) according to standard protocols; red blood cells were 
lysed with ACK buffer. Intrahepatic lymphocytes were prepared 
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as described (42). Total cell number was quantified by Guava 
Easycytes with Guava Express software (Guava). For surface stain- 
ing, single cell suspension was stained with surface markers and 
analyzed on a CyAn ADP flow cytometer (Dako). For intracel-
lular staining, cells were first stained with surface markers and 
then fixed and permeabilized with cytofix/cytoperm buffer (BD 
Bioscience), followed by intracellular staining. Data were ana-
lyzed using Summit4.3 software (Dako).
T cell stimulation and intracellular 
cytokine staining
Splenocytes from humanized mice were stimulated ex vivo 
with PMA (phorbol 12-myristate 13-acetate) (50  ng/ml) and 
iono mycin (1 μM) (Sigma, St. Louis, MO, USA) for 4 h in the 
presence of brefeldin A (BioLegend). Cell were then fixed and 
permeabilized with cytofix/cytoperm buffer (BD Biosciences), 
and intracellular staining was then performed.
Tlr-l Treatment In Vivo
CpG-B (ODN 2006), R848, and poly I:C were all purchased from 
InvivoGen. For in vivo treatment, humanized mice were treated 
with 50  μg/mouse of CpG-B, poly I:C or 20  μg/mouse R848 
through i.p. injection.
Detection of cytokines in Plasma
Human pan IFN-α (subtypes 1/13, 2, 4, 5, 6, 7, 8, 10, 14, 16, 
and 17) were detected by enzyme-linked immunosorbent assay 
using the human IFN-α pan ELISA kits purchased from Mabtech 
(Nacka Strand, Sweden). Human IL-6 in plasma of humanized 
mice were detected by immunology multiplex assay (Luminex) 
(Millipore, Billerica, MA, USA).
hiV-1 infection of humanized Mice
The CCR5-tropic strain of HIV-1 (JR-CSF) was generated by 
transfection of 293T cells (ATCC) with plasmid containing full 
length HIV-1 (JR-CSF) genome. Humanized mice with stable 
human leukocyte reconstitution were anesthetized and infected 
with HIV-1 (JR-CSF) (10 ng p24/mouse) through retro-orbital 
injection.
hiV-1 genomic rna Detection  
in Plasma
HIV-1 RNA was purified from the plasma with the QIAamp® 
Viral RNA Mini Kit. The RNA was then reverse transcribed and 
quantitatively detected by real-time PCR using the TaqMan® Fast 
Virus 1-Step PCR kit (ThermoFisher Scientific). The primers 
used for detecting the HIV Gag gene were (5′-GGTGCGAGA 
GCGTCAGTATTAAG-3′ and 5′-AGCTCCCTGCTTGCCCAT 
A-3′). The probe (FAM-AAAATTCGGTTAAGGCCAGGGGGA 
AAGAA-QSY7) used for detection was ordered from Applied 
Biosystems, and the reactions were set up following the manu-
facturer’s guidelines and were run on the QuantStudio 6 Flex PCR 
system (Applied Biosystems). The detection limit of the real-time 
PCR reaction is four copies per reaction. Accordingly, the limit 
of detection of the assay with 50 µl of blood is 400 copies/ml in 
humanized mice.
combination antiretroviral Therapy
Food formulated with antiretroviral individual drug was pre-
pared as reported with elevated dose modifications (34). In 
brief, tablets of emtricitabine and tenofovir disoproxil fumarate 
(Truvada®; Gilead Sciences) and raltegravir (Isentress®; Merck) 
were crushed into fine powder and manufactured with TestDiet 
5B1Q feed (Modified LabDiet 5058 with 0.12% amoxicillin) into 
1/2’’ irradiated pellets. Final concentrations of drugs in the food 
were 4,800 mg/kg raltegravir, 1,560 mg/kg tenofovir disoproxil, 
and 1,040 mg/kg emtricitabine. The estimated drug daily doses 
were 768 mg/kg raltegravir, 250 mg/kg tenofovir disoproxil, and 
166 mg/kg emtricitabine.
In Vivo iFnar1 Blocking antibody 
Treatments
The α-IFNAR1 monoclonal antibody (mAb) was generated as 
previous reported (29). To block type-I interferon (IFN-I) sign-
aling during chronic HIV-1 infection, humanized mice were 
treated i.p. with IFNAR1 blocking antibodies twice a week with 
the dose 400 µg/mouse at the first injection and 200 μg/mouse 
for the following treatments. Cohorts of mice were randomi- 
zed into different treatment groups by level of HIV-1 RNA in 
plasma.
cell-associated hiV-1 Dna Detection
To measure total cell-associated HIV-1 DNA, nucleic acid was 
extracted from spleen and BM cells using the DNeasy Blood & 
Tissue Kit (Qiagen). HIV-1 DNA was quantified by real-time 
PCR. DNA from serial dilutions of ACH2 cells, which contain 
one copy of HIV genome in each cell, was used to generate a 
standard curve.
Viral Outgrowth assay
Viral outgrowth assay was performed as reported (43). Serial 
dilutions of human cells from splenocytes of humanized mice 
(1 × 106, 2 × 105, and 4 × 104 human cells) were stimulated with 
PHA (2  µg/ml) and IL-2 (100  U/ml) for 24  h. MOLT4/CCR5 
cells were added on day 2 to enhance the survival of the cultured 
cells as well as to support and facilitate further HIV-1 replication. 
Culture medium containing IL-2 (NIH AIDS reagents program) 
and T cell growth factor (homemade as describe in the standard 
protocol) was replaced on days 5 and 9. After 7 and 14 days of 
culture, supernatant from each well was harvested, and HIV-1 
RT-qPCR was performed to score viral outgrowth. Estimated 
frequencies of cells with replication-competent HIV-1 were 
determined by maximum likelihood statistics (43).
statistical analysis
In all other experiments, significance levels of data were determ-
ined by using Prism5 (GraphPad Software). Experiments were 
analyzed by two-tailed Student’s t-test, or by one-way analysis 
of variance (ANOVA) and Bonferroni’s post hoc test according 
to the assumptions of the test, as indicated for each experi-
ment. A P value less than 0.05 was considered significant. The 
number of animals and replicates is specified in each figure 
legend.
FigUre 1 | Comparison of human immune cell reconstitution in peripheral 
blood of NRG-hu HSC and NRG-hu Thy/HSC mice. NRG-hu HSC and 
NRG-hu Thy/HSC mice were generated as indicated in Section “Materials 
and Methods.” (a) Summarized data show percentage of human leukocytes 
(hCD45+) in total peripheral blood leukocytes 12 weeks after reconstitution. 
Shown are combined data from two cohorts of NRG-hu HSC mice (n = 27) 
and NRG-hu Thy/HSC mice (n = 35) reconstituted with HSCs ± thymus from 
the same human donor. (B–h) Summarized data show percentage of human 
T cells (CD3+), B cells (CD19+), NK cells (CD3−CD56+), plasmacytoid dendritic 
cells (pDCs) (CD3−CD19−HLA-DR+CD4+CD123+), and monocytes 
(CD3−CD19−HLA-DR+CD14+) in human CD45+ cells (B,e–h) and percentage 
of human CD4 T and CD8 T cells in human CD3 T cells (c,D). Shown are 
representative data (B–h) from n = 18 (NRG-hu HSC) and n = 10 (NRG-hu 
Thy/HSC) hu-mice reconstituted with HSCs ± thymus from same donor. 
Each dot represents one individual mouse; bars indicate mean (*P < 0.05, 
**P < 0.01, and ***P < 0.001, by unpaired, two-tailed Student’s t-test).
4
Cheng et al. Humanized Hu-HSC and Hu-Thy/HSC Mice
Frontiers in Immunology | www.frontiersin.org April 2018 | Volume 9 | Article 817
resUlTs
human lymphoid and Myeloid lineage 
cells are reconstituted in Peripheral 
Blood of Both nrg-hu hsc and  
nrg-hu Thy/hsc Mice
To compare the level of human immune reconstitution in 
humanized mice (hu-mice) transplanted with human HSCs 
only (NRG-hu HSC) or with human HSCs plus thymus tissue 
(NRG-hu Thy/HSC), we reconstituted newborn NRG mice 
with human fetal liver derived CD34+ HSCs (NRG-hu HSC) 
or reconstituted 6- to 8-week-old NRG mice with human fetal 
liver derived CD34+ HSCs together with fetal thymus tissue 
(NRG-hu Thy/HSC) from the same donor. The difference 
between the NRG-hu Thy/HSC model and the hu-BLT model 
is that we only transplant thymus tissue but not fetal liver 
tissue under the kidney capsule. The other difference is that 
we transplant human HSCs within 3  h after human thymus 
transplantation. As reported in hu-BLT mice (14, 15), human 
thymic organoid was well developed and showed long-term 
sustained thymopoiesis in NRG-hu Thy/HSC mice (Figure S1 in 
Supplementary Material). Human immune cell reconstitution in 
the peripheral blood was detected by flow cytometry 12 weeks 
after transplantation. All major human CD45+ leukocyte subsets 
including T  cells (CD3+), B  cells (CD19+), NK  cells (CD3− 
CD56+), monocytes (CD3−CD19−HLA−DR+CD14+), and pDCs 
(CD3−CD19−HLA−DR+CD4+CD123+) were detected in periph-
eral blood of both NRG-hu HSC and NRG-hu Thy/HSC mice 
(Figure 1; Figure S1 in Supplementary Material). Similar level 
of human CD45+ cells was found in NRG-hu HSC (65.3 ± 5.3%) 
and NRG-hu Thy/HSC (68.8 ±  3.1%) mice (Figure  1A). The 
percentage of human T  cells within human CD45+ leukocytes 
was significantly higher in NRG-hu Thy/HSC mice (61.1 ± 3.2%) 
compared with the level in NRG-hu HSC mice (20.1 ±  3.4%) 
(Figure  1B). The result indicated that fetal liver/thymus 
“sandwich” structure (14, 15) is not essential for the long-term 
functioning human thymus development if human CD34+ HSCs 
were transplanted immediately after thymus transplantation. 
Progenitor cells derived from CD34+ HSCs can serve as the 
source of thymocyte progenitors. Both CD4 and CD8 T  cells 
were developed in NRG-hu HSC and NRG-hu Thy/HSC mice 
(Figures  1C,D). The ratio of CD4 T  cells to CD8 T  cells was 
slightly higher in NRG-hu Thy/HSC mice compare to NRG-hu 
HSC mice (Figures 1C,D). The percentage of human B cells was 
65.8 ± 3.3% in NRG-hu HSC mice and 33 ± 4.9% in NRG-hu 
Thy/HSC mice (Figure 1E). The percentages of human NK cells, 
pDCs, and monocytes were also lower in NRG-hu Thy/HSC mice 
compared with NRG-hu HSC mice (Figures 1F–H).
human leukocytes are equally 
reconstituted in lymphoid Organs in Both 
nrg-hu hsc and nrg-hu Thy/hsc Mice
We also detected human immune reconstitution in lymphoid 
organs including spleen, mLNs, liver, and BM of NRG-hu HSC 
and NRG-hu Thy/HSC mice. The percentage of human CD45+ 
cell and total number of human CD45+ cells were comparable in 
spleen, mLN, and BM between NRG-hu HSC and NRG-hu Thy/
HSC mice (Figures 2A,B). The level of human immune cells in the 
liver was slightly higher in NRG-hu Thy/HSC mice (95.7 ± 0.8%) 
compared with the NRG-hu HSC mice (85.6 ± 2.2%), consistent 
with the higher number of human CD45+ cells in the liver in 
NRG-hu Thy/HSC mice (Figures 2A,B).
similar Phenotype and Function of human 
T and B cells Developed in nrg-hu hsc 
and nrg-hu Thy/hsc Mice
We next determined the phenotype and function of human 
T  cells and B  cells from spleen of NRG-hu HSC and NRG-hu 
Thy/HSC mice. As in the peripheral blood, both the percent-
age and number of CD3+ T  cells were higher in the spleen of 
NRG-hu Thy/HSC mice (Figures  3A,B). The percentages of 
CD4 and CD8 T  cells in total T  cells did not show difference 
in the spleen between these two models (Figure  3A). Most of 
the T cells from both NRG-hu HSC (64.4 ± 3.1%) and NRG-hu 
Thy/HSC (64.3 ±  5.8%) showed naïve phenotype at 20  weeks 
posttransplantation (Figure  3C). The function of T  cells from 
both humanized mouse models were equal as they produced 
FigUre 2 | Comparison of total human immune cell reconstitution in 
lymphoid organ of NRG-hu HSC and NRG-hu Thy/HSC mice. NRG-hu  
HSC and NRG-hu Thy/HSC mice were terminated at 20 weeks after 
reconstitution and human immune cells in lymphoid organs were detected  
by flow cytometry. Summarized data show percentage (a) and number  
(B) of human leukocytes (hCD45+) in spleen, mesenteric lymph nodes 
(mLNs), bone marrow (BM), and intrahepatic leukocytes (IHL) of NRG-hu 
HSC and NRG-hu Thy/HSC mice. Shown are representative data from 
n = 15 (NRG-hu HSC) and n = 12 (NRG-hu Thy/HSC) hu-mice per group 
reconstituted with HSCs ± thymus from same donor. Each dot represents 
one individual mouse; bars indicate mean (*P < 0.05 and ***P < 0.001, by 
unpaired, two-tailed Student’s t-test).
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similar level of IFN-γ and IL-2 in response to mitogen stimulation 
ex vivo (Figure 3D). No spontaneous IFN-γ and IL-2 production 
by T cells was detected from either the NRG-hu HSC or NRG-hu 
Thy/HSC mice.
As in the peripheral blood, the percentage and number of B cells 
in the spleen were lower in NRG-hu Thy/HSC mice compared 
with the NRG-hu HSC mice (Figure 3E). It has been reported 
that human B cells developed in humanized mice were immature 
and cannot produce significant level of antigen-specific IgG by 
vaccination (44–46). We also compared the phenotype of B cells 
from both NRG-hu HSC and NRG-hu Thy/HSC mice and found 
that they both express high level of immature marker CD10 
(Figure 3F). The expression of CD10 on B cells from NRG-hu 
Thy/HSC mice was slightly higher (Figure 3F), indicating that 
co-transplantation of thymus had minor effect on the maturation 
of B cells in NRG-hu Thy/HSC mice.
innate immune cells Were Developed in 
spleen of Both nrg-hu hsc and nrg-hu 
Thy/hsc Mice and responded similarly  
to Tlr-ls stimulation
We compared the reconstitution of human innate immune 
cells including pDCs, mDCs and monocytes/macrophages in 
the spleen of NRG-hu HSC and NRG-hu Thy/HSC mice. The 
percentage and number of pDC (Figure  4A) and monocytes/
macrophage (Figure 4B) were comparable, while there were more 
mDCs in the spleen of NRG-hu HSC mice compared with 
NRG-hu Thy/HSC mice (Figure 4C).
To detect the function of innate immune cells developed 
in NRG-hu HSC and NRG-hu Thy/HSC mice, we treated the 
mice in vivo with the TLR9-ligands CpG-B, the TLR7/8-L R848 
and the TLR3-L poly I:C and detected cytokine production 
in the serum. We found that all the three TLR-Ls induced sig- 
nificant levels of IFN-α and IL-6 in both NRG-hu HSC and 
NRG-hu Thy/HSC mice (Figure 4D). The induction of IFN-α 
by poly(I:C) and R848 stimulation is slightly lower in NRG-hu 
Thy/HSC mice compared with NRG-hu HSC mice (Figure 4D) 
which probably due to the lower number of mDC developed 
in NRG-hu Thy/HSC mice compared with NRG-hu HSC mice 
(Figure 4C).
In summary, most human lymphoid and myeloid lineage cells 
are reconstituted in both NRG-hu HSC and NRG-hu Thy/HSC 
mice, with human T cells predominantly developed in NRG-hu 
Thy/HSC mice, while NRG-hu HSC mice support better human 
B cell and myeloid cell development. The phenotype and function 
of human immune cells developed in NRG-hu HSC mice and 
NRG-hu Thy/HSC mice are similar.
nrg-hu hsc and nrg-hu Thy/hsc Mice 
support similar level of hiV-1  
replication In Vivo
We and others have reported that both NRG-hu HSC and 
NRG-hu Thy/HSC mice supported HIV-1 replication in  vivo 
(7, 8, 47). Here we compared the HIV-1 replication kinetics in 
NRG-hu HSC mice and NRG-hu Thy/HSC mice transplanted 
with HSCs ± thymus from the same donor tissue. We found the 
viremia reached to peak level at 2 weeks postinfection (wpi) in 
NRG-hu HSC mice (Figure  5A), while in NRG-hu Thy/HSC 
mice, the viremia reached the peak level at 4 wpi (Figure 5B). At 
2 wpi, NRG-hu HSC mice supported efficient HIV-1 replication 
in nearly all mice (98%) but NRG-hu Thy/HSC mice supported 
HIV-1 replication in about 73% of infected mice (Figure 5B). The 
results suggest that the immune cells in NRG-hu Thy/HSC mice 
may control/delay HIV-1 replication at the early stage of HIV-1 
infection. At 4 wpi, all the infected BLT mice showed similar 
viremia as detected in NRG-hu HSC mice and sustained through 
10 wpi when we terminated the mice (Figures 5A–C). HIV-1 p24 
levels in CD4 T cells from the spleen were similar in NRG-hu 
HSC and NRG-hu Thy/HSC mice at 10 wpi (Figures  5D,E). 
In summary, the results indicated that both the NRG-hu HSC 
and NRG-hu Thy/HSC mice support similar levels of HIV-1 
replication, although there was a 2 weeks delay reaching the peak 
viremia in NRG-hu Thy/HSC mice.
hiV-1 infection induces similar levels  
of T cell Depletion, activation, and 
exhaustion in nrg-hu hsc and  
nrg-hu Thy/hsc Mice
We next detected HIV-1 induced immunopathology including 
T  cell depletion, activation and dysfunction in both NRG-hu 
FigUre 3 | Phenotype and function of human T and B cells from NRG-hu HSC and NRG-hu Thy/HSC mice. NRG-hu HSC and NRG-hu Thy/HSC mice were 
terminated at 20 weeks after reconstitution. (a,B) Summarized data show percentage (a) and number (B) of total human T cells, CD4 T and CD8 T cells in spleen 
of NRG-hu HSC and NRG-hu Thy/HSC mice. (c) Representative dot plots and summarized data show the expression of CD45RA and CCR7 on CD3 T cells from 
the spleen of NRG-hu HSC and NRG-hu Thy/HSC mice detected by flow cytometry. Shown (a–c) are data from n = 15 (NRG-hu HSC) and n = 12 (NRG-hu Thy/
HSC) hu-mice per group reconstituted with HSCs/thymus from same donor. (D) Splenocytes were stimulated ex vivo with PMA/ionomycin for 4 h followed by 
intracellular cytokine staining. Representative dot plots and summarized data show percentages of IFN-γ and IL-2 producing CD4 and CD8 T cells. Shown are  
data from n = 10 (NRG-hu HSC) and n = 7 (NRG-hu Thy/HSC) hu-mice per group. (e) Summarized data showed percentage and number of total human B cells  
in spleen of NRG-hu HSC and NRG-hu Thy/HSC mice. (F) Representative dot plots and summarized data show expression of CD10 on B cells from the spleen of 
NRG-hu HSC and NRG-hu Thy/HSC mice. Shown (e,F) are data from n = 15 (NRG-hu HSC) and n = 12 (NRG-hu Thy/HSC) hu-mice per group reconstituted with 
HSCs ± thymus from the same donor. Each dot represents one individual mouse; bars indicate mean (*P < 0.05, **P < 0.01, and ***P < 0.001, by unpaired, 
two-tailed Student’s t-test).
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HSC and NRG-hu Thy/HSC mice. We found that HIV-1 induced 
similar level of total human CD45+ cells and human T  cells 
depletion in both NRG-hu HSC and NRG-hu Thy/HSC mice 
(Figures  6A,B). HIV-1 infection also induced similar level of 
CD38 and HLA-DR expression on CD8 T cells in both NRG-hu 
HSC and NRG-hu Thy/HSC mice (Figures 6C,D). In addition, 
we detected the T cells exhaustion marker PD-1 expression and 
found that both CD8 T cell from NRG-hu HSC and NRG-hu Thy/
HSC mice expressed higher level of PD-1 than mock-infected 
mice, which indicated HIV-1 induced human T cell exhaustion 
in both humanized mouse models (Figures  6E,F). The results 
indicate that HIV-1 infection induced T  cell depletion, activa-
tion and exhaustion to similar levels in both NRG-hu HSC and 
NRG-hu Thy/HSC mice.
carT efficiently inhibits hiV-1 replication 
in Both nrg-hu hsc and nrg-hu  
Thy/hsc Mice
We and others have shown before that as in human patients, 
cART can efficiently inhibit HIV-1 replication in hu-mice 
(29, 33, 34, 38). We compared the efficacy of cART to inhibit 
HIV-1 replication in NRG-hu HSC mice and NRG-hu Thy/
HSC mice. The results indicate that plasma viremia decreased to 
undetectable levels (<400 genome copies/ml) in all HIV-infected 
NRG-hu HSC and NRG-hu Thy/HSC mice within 3  weeks 
after cART treatment (Figures  7A,B). Similar to cART-treated 
patients, HIV-1 reservoirs persisted stably in both NRG-hu 
HSC and NRG-hu Thy/HSC mice and virus rebounded rapidly 
FigUre 4 | Development and function of human innate immune cells from NRG-hu HSC and NRG-hu Thy/HSC mice. NRG-hu HSC and NRG-hu Thy/HSC  
mice were terminated at 20 weeks after reconstitution. (a–c) Summarized data show percentage and number of total human plasmacytoid dendritic cells (pDCs) 
(CD3−CD19−HLA-DR+CD4+CD123+), monocytes or macrophage (CD3−CD19−HLA-DR+CD14+), and myeloid dendritic cell (mDC) (CD3−CD19−HLA-
DR+CD11c+CD14−) in spleen. Shown (a–c) are data from n = 15 (NRG-hu HSC) and n = 12 (NRG-hu Thy/HSC) hu-mice per group reconstituted with 
HSCs ± thymus from same donor. (D) NRG-hu HSC and NRG-hu Thy/HSC mice were injected intraperitoneally with CpG-B (50 μg/mouse), poly I:C (50 μg/mouse), 
R848 20 μg/mouse, or PBS. Plasma was collected at different time points posttreatment. IFN-α levels in plasma were detected at 24 h after treatment. IL-6 level 
was detected at 4 h after treatment. Shown (D) are data from three to four mice each group for each treatment conditions. Each dot represents one individual 
mouse; bars indicate mean (*P < 0.05 and **P < 0.01, by unpaired, two-tailed Student’s t-test).
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after cART cessation (Figures 7C,D). HIV-1 rebounded in 60% 
NRG-hu HSC mice at 1-week post cART cessation and in 100% 
NRG-hu HSC mice at 2 weeks post cART cessation (Figure 7E). 
Similarly, HIV-1 rebounded in 50% NRG-hu Thy/HSC mice at 
1-week post cART cessation and in 100% NRG-hu Thy/HSC mice 
at 2 weeks post cART cessation (Figure 7F).
iFnar Blockade During carT-suppressed 
hiV-1 infection reverses aberrant immune 
activation and exhaustion Phenotype  
of human T cells
We next determined whether IFNAR blockade can reverses 
aberrant immune activation and exhaustion phenotype of human 
T cells in both NRG-hu HSC and NRG-hu Thy/HSC mice. We 
found that in both HIV-1 infected NRG-hu HSC and NRG-hu Thy/
HSC mice, cART alone significantly rescued the number of human 
CD4 and CD8 T cells (Figures 8A,B), however, it only slightly 
decreased the expression level of CD38/HLA-DR (Figures 8C,D) 
and PD-1 on CD8 T  cells (Figures  8E,F). CD8 T  cells from 
both cART-treated NRG-hu HSC and NRG-hu Thy/HSC mice 
still expressed significantly higher levels of activation marker 
(Figures  8C,D) and exhaustion marker PD-1 (Figures  8E,F) 
compared with uninfected hu-mice. Interestingly, IFNAR block-
ade significantly reversed aberrant CD8 T-cell activation and 
exhaustion in the presence of cART in both NRG-hu HSC and 
NRG-hu Thy/HSC mice (Figures 8C–F).
iFnar Blockade reduce hiV-1 reservoirs 
in Both hiV-1 infected nrg-hu hsc and 
nrg-hu Thy/hsc Mice Under carT
Combined antiretroviral therapy is able to suppress HIV-1 
replication but does not eradicate HIV reservoir, which cause 
virus rebound after cART interruption. We have reported before 
that during chronic phase of HIV-1 infection in humanized mice, 
blockade of IFN-I signaling using a mAb targeting to IFN-I 
receptor (IFNAR) reduces the level of T cell activation, reverses 
T cell exhaustion, and improves HIV-specific CD8+ T cells (29). 
Most strikingly, we found that IFNAR blockade during cART 
administration markedly reduced HIV-1 reservoirs (29). Here 
we compared the effect of IFNAR blockade in HIV-1 reservoir 
reduction in NRG-hu HSC and NRG-hu Thy/HSC mice. We 
treated HIV-1-infected NRG-hu HSC and NRG-hu Thy/HSC 
mice that were fully cART-suppressed with α-IFNAR1 mAb for 
3 weeks during 7–10 wpi (Figures 9A,B). Interestingly, IFNAR 
blockade led to low blips of HIV-1 replication, which returned to 
undetectable levels after stopping α-IFNAR1 mAb treatment, in 
the presence of cART in both NRG-hu HSC and NRG-hu Thy/
HSC mice (Figures 9A,B). We next analyzed the HIV-1 reser-
voir size in lymphoid organs 2 weeks after IFNAR blockade in 
both NRG-hu HSC and NRG-hu Thy/HSC mice. We measured 
cell-associated HIV-1 DNA by PCR, and replication-competent 
HIV-1 by the quantitative virus outgrowth assay. We found that 
IFNAR blockade reduced cell-associated HIV-1 DNA by 10.8-fold 
in the spleen of NRG-hu HSC mice (Figure 9C) and by 7.9-fold 
FigUre 5 | HIV-1 replication kinetics in NRG-hu HSC and NRG-hu Thy/HSC mice in vivo. NRG-hu HSC and NRG-hu Thy/HSC mice were infected with HIV-1 at 
12–13 weeks postinfection (wpi). (a,B) Plasma HIV-1 genomic RNA levels were measured at indicated time points in each NRG-hu HSC (a) and NRG-hu Thy/HSC 
(B) mice. Shown are representative data from n = 3 (NRG-hu HSC/Mock), n = 5 (NRG-hu HSC/HIV-1), n = 3 (NRG-hu Thy/HSC/Mock), and n = 5 (NRG-hu Thy/
HSC/HIV-1) mice transplanted with HSCs ± thymus from the same donor. The broken horizontal line indicates the limit of detection (400 copies/ml). (c) Summary 
data show plasma HIV-1 genomic RNA levels at 2 and 4 wpi from NRG-hu HSC (n = 46) and NRG-hu Thy/HSC (n = 44) mice. Shown (c) are combined data from 
five cohorts of NRG-hu HSC mice and six cohorts of NRG-hu Thy/HSC mice. The viral infection data were collected previously by the laboratory. (D,e) 
Representative FACS plots and summarized data show percentages of HIV-1 p24-positive CD4 T cells (CD3+CD8−) in the spleen of NRG-hu HSC (D) and NRG-hu 
Thy/HSC (e) mice at 10 wpi. Shown are representative data from n = 3 (NRG-hu HSC/Mock), n = 5 (NRG-hu HSC/HIV-1), n = 3 (NRG-hu Thy/HSC/Mock), and 
n = 5 (NRG-hu Thy/HSC/HIV-1) mice transplanted with HSCs ± thymus from the same donor. Each dot represents one individual mouse; bars indicate mean 
(*P < 0.05, **P < 0.01, and ***P < 0.001, by unpaired, two-tailed Student’s t-test).
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in NRG-hu Thy/HSC mice (Figure 9D). More importantly and 
consistently, IFNAR blockade significantly reduced the size of 
replication-competent HIV-1 reservoirs measured by quantita-
tive virus outgrowth assay in both NRG-hu HSC and NRG-hu 
Thy/HSC mice (Figures 9E,F).
Taken together, we conclude that both NRG-hu HSC and 
NRG-hu Thy/HSC mouse models are valuable tools for the study 
of HIV-1 replication, pathogenesis and therapeutics.
DiscUssiOn
Humanized mice with human immune cells are highly relevant and 
robust models for HIV-1 study (6–8). The models are generated 
via transplantation of CD34+ HSCs and/or implantation of human 
tissue into immunodeficient mice. There are different humanized 
mouse models available as well as different means to prepare them 
(6, 7, 9). The degree of human immune system reconstitution can 
vary between different models, and between different batches of 
HSCs and/or tissue donors, and non-standardized operating pro-
cedure between laboratories. Also, HIV-1 infection, replication 
and HIV-1 induced pathology can vary between different models 
and dependant on which HIV-1 virus strain is used. These factors 
make researchers, especially those who have limited experiences 
on humanized mouse models difficult to decide which model to 
choose for their studies. Here we performed a comprehensive 
parallel comparison of systemic immune reconstitution and 
HIV-1 replication, HIV-1 induced pathology and their response 
to cART and immunotherapy between two humanized mouse 
models, the NRG-hu HSC and NRG-hu Thy/HSC models. We 
used NRG-hu HSC and NRG-hu Thy/HSC mice transplanted with 
HSCs without or with thymus fragment from same donors into 
same background of immunodeficient mice in our experiment 
to minimize the variation factors. Our results indicate that both 
NRG-hu HSC and NRG-hu Thy/HSC mice support significant 
level of human immune reconstitution and comparable level of 
HIV-1 replication, immunopathology and responses to ART and 
immune therapy.
We and others have reported that all the major human lym-
phoid and myeloid lineage cells are developed in both NRG-hu 
HSC mice and hu-BLT mice (10–20). However, no study has per-
formed to parallelly compare the human immune reconstitution 
in these two models which transplanted with HSCs ±  thymus 
from same donor into the same background of immunodeficient 
mice. In the NRG-hu Thy/HSC model, we co-transplanted CD34+ 
HSCs by intravenous injection within 3 h after thymus fragment 
(without fetal liver fragment) transplantation. Human thymic 
organoid developed under the kidney capsule in our NRG-hu 
Thy/HSC as well as reported in hu-BLT mice which indicated 
FigUre 6 | HIV-1-induced immunopathology in NRG-hu HSC and NRG-hu Thy/HSC mice. NRG-hu HSC and NRG-hu Thy/HSC mice were infected with HIV-1. 
Mice were sacrificed at 10 weeks postinfection. (a,B) Numbers of total human leukocytes, CD3+ T cells, CD4 T cells (CD3+CD8−), and CD8 T cells (CD3+CD8−)  
and in spleens of NRG-hu HSC (a) and NRG-hu Thy/HSC (B) mice. (c,D) Representative FACS plots and summarized data show the expression of CD38 and 
HLA-DR on CD8 T cells from spleen of NRG-hu HSC (c) and NRG-hu Thy/HSC (D) mice. (e,F) Representative FACS plots and summarized data show the 
expression of PD-1 on CD8 T cells from spleen of NRG-hu HSC (e) and NRG-hu Thy/HSC (F) mice. Shown are representative data from n = 3 (NRG-hu HSC/
Mock), n = 5 (NRG-hu HSC/HIV-1), n = 3 (NRG-hu Thy/HSC/Mock), and n = 5 (NRG-hu Thy/HSC/HIV-1) mice reconstituted with HSCs/thymus from the same 
donor. Each dot represents one individual mouse; bars indicate mean (*P < 0.05, **P < 0.01, and ***P < 0.001, by unpaired, two-tailed Student’s t-test).
FigUre 7 | Similar efficacy of combined antiretroviral therapy (cART) response in HIV-1-infected NRG-hu HSC and NRG-hu Thy/HSC mice. (a,B) NRG-hu HSC 
(n = 6) and NRG-hu Thy/HSC mice (n = 7) reconstituted with HSCs ± thymus from the same donor were infected with HIV-1 and treated with cART from 4 to 
11 weeks postinfection. HIV-1 genomic RNA levels in the plasma were detected at indicated time points. (c,D) A different cohort of NRG-hu HSC (n = 12) and 
NRG-hu Thy/HSC mice (n = 10) were infected with HIV-1 and treated with cART for 9 weeks. HIV-1 genomic RNA levels in the plasma were detected before  
and after cART discontinuation at indicated time points. The broken horizontal line indicates the limit of detection (400 copies/ml). (e,F) Kinetic analysis of HIV-1 
rebound post-cART cessation. Shown (c–e) are combined data from n = 12 (NRG-hu HSC) and n = 10 (NRG-hu Thy/HSC) mice.
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FigUre 8 | IFNAR blockade reduces activation and PD-1 expression on CD8 T cells in both HIV-1 infected NRG-hu HSC and NRG-hu Thy/HSC mice under 
combined antiretroviral therapy (cART). NRG-hu HSC and NRG-hu Thy/HSC mice infected with HIV-1 were treated with cART from 4 to 12 weeks postinfection 
(wpi). From 7 to 10 wpi, the cART-treated mice were injected with α-IFNAR1 antibody or isotype control mIgG2a antibody. Mice were sacrificed at 12 wpi.  
(a,B) Summarized data show numbers of human CD4 and CD8 T cells from spleens of NRG-hu HSC (a) and NRG-hu Thy/HSC (B) mice. (c,D) Summarized  
data show percent HLA-DR+CD38+ of CD8 T cells from spleens of NRG-hu HSC (c) and NRG-hu Thy/HSC (D) mice. (e,F) Summarized data show percent PD-1+ 
of CD8 T cells from spleens of NRG-hu HSC (e) and NRG-hu Thy/HSC (F) mice. Shown are representative data from n = 3 (NRG-hu HSC/Mock), n = 3 (NRG-hu 
HSC/HIV-1), n = 4 (NRG-hu HSC/HIV-1/cART/mIgG2a), n = 4 (NRG-hu HSC/HIV-1/cART/α-IFNAR1), n = 4 (NRG-hu Thy/HSC/Mock), n = 4 (NRG-hu Thy/HSC/
HIV-1), and n = 4 (NRG-hu Thy/HSC/HIV-1/cART/mIgG2a), n = 4 (NRG-hu Thy/HSC/HIV-1/cART/α-IFNAR1) mice. Each dot represents one individual mouse;  
bars indicate mean (*P < 0.05, **P < 0.01, and ***P < 0.001, by one-way analysis of variance and Bonferroni’s post hoc test).
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that the fetal liver/thymus “sandwich” are not essential for 
thymic organoid development. Progenitor cells derived from 
CD34+ HSCs can serve as the source of thymocyte progenitors. 
It should be noted that the fetal liver fragments co-transplanted 
with thymus fragments in the BLT or SCID-hu Thy/Liv (48) mice 
also provide mostly human HSC/progenitors and no other liver-
related functions. Our results indicate that similar level of total 
human CD45+ cells were developed in peripheral blood, spleen, 
mLNs, and BM of both NRG-hu HSC and NRG-hu Thy/HSC 
mice transplanted with HSCs ±  thymus from same donor. We 
also found that all the major human lymphoid and myeloid line-
age including T, B, NK cells, monocytes/macrophages, mDC, and 
pDC were developed in both NRG-hu HSC mice and NRG-hu 
Thy/HSC mice. The major difference between these two models 
is that human T cells are predominantly developed in NRG-hu 
Thy/HSC mice due to more efficient T cell development in human 
thymus tissue (or xeno-reactive T  cells) in NRG-hu HSC-Thy 
mice. This may lead to preferential reconstitution of T cells and 
reduced NK/monocyte/pDC engraftment in NRG-hu HSC-Thy 
mice (Figures 1 and 3).
Our results indicated that majority of human T  cells from 
both NRG-hu HSC and NRG-hu Thy/HSC mice were with naïve 
phenotype and they responded similarly to mitogen stimulation. 
However, it is important to point out that human T  cells can 
develop in the presence of human thymic epithelium, resulting in 
human HLA class I and class II restriction in NRG-hu Thy/HSC 
mice (14, 15, 40). While in NRG-hu HSC mice, human T cells 
are produced in the mouse thymus and presumed to be educated 
in the context of mouse MHC (10–13). To study human HLA-
restricted immune response in NRG-hu HSC mice, an immune-
compromised non-obese diabetic/SCID/IL2rg−/− strain (NSG) 
with homozygous expression of HLA class I heavy chain and 
light chain (NSG-HLA-A2/HHD) was generated (49). Human 
CTLs developing in the NSG-HLA-A2/HHD mice recognized 
EBV-derived peptides in an HLA-restricted manner and showed 
HLA-restricted cytotoxicity against EBV-infected human B cells 
(49). We also reported that HIV-1 infection can induce HIV-1 
antigen-specific, HLA-A2-restricted CD8 T  cell responds in 
humanized NSG-HLA-A2/HHD mice (31).
Both NRG-hu HSC and NRG-hu Thy/HSC mice support 
HIV-1 replication in vivo. Our results show that plasma HIV-1 
viremia reached to peak levels at 2 wpi in NRG-hu HSC mice, 
while the peak viremia appeared at 4 wpi in NRG-hu Thy/HSC 
mice. The results suggest that anti-HIV-1 immunity at the early 
FigUre 9 | IFNAR blockade reduce HIV-1 reservoir in both HIV-1 infected NRG-hu HSC and NRG-hu Thy/HSC mice under combined antiretroviral therapy (cART). 
NRG-hu HSC and NRG-hu Thy/HSC mice infected with HIV-1 were treated with cART from 4 to 12 weeks postinfection (wpi). From 7 to 10 wpi, the cART-treated 
mice were injected with α-IFNAR1 antibody or isotype control mIgG2a antibody. (a,B) HIV-1 genomic RNA levels in the plasma of NRG-hu HSC (a) and NRG-hu 
Thy/HSC (B) mice. (c,D) Cell-associated HIV-1 DNA in human cells from spleen of NRG-hu HSC (c) and NRG-hu Thy/HSC (D) mice was quantified by PCR. (e,F) 
Replication-competent HIV-1 viruses from unfractionated human CD45+ cells from spleen of NRG-hu HSC (e) and NRG-hu Thy/HSC (F) mice were detected by the 
quantitative virus outgrowth assay. The frequency was determined by maximum likelihood statistics. The infectious units in CD4 T cells were calculated based on the 
percentage of CD4 T cells in total human CD45+ cells. Shown are representative data from n = 3 (NRG-hu HSC/Mock), n = 3 (NRG-hu HSC/HIV-1), n = 4 (NRG-hu 
HSC/HIV-1/cART/mIgG2a), n = 4 (NRG-hu HSC/HIV-1/cART/α-IFNAR1), n = 4 (NRG-hu Thy/HSC/Mock), n = 4 (NRG-hu Thy/HSC/HIV-1), n = 4 (NRG-hu Thy/
HSC/HIV-1/cART/mIgG2a), n = 4 (NRG-hu Thy/HSC/HIV-1/cART/α-IFNAR1) mice. Each dot represents one individual mouse; bars indicate mean (*P < 0.05, 
**P < 0.01, and ***P < 0.001, by one-way analysis of variance and Bonferroni’s post hoc test).
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stage of HIV-1 infection is better in NRG-hu Thy/HSC mice. The 
better HLA-restricted anti-HIV-1 T  cells response in NRG-hu 
Thy/HSC mice (23) may contribute to the delay of peak viremia. 
However, other unknown factors, such as the difference in immune 
subset reconstitution or donor genetics, may also lead to the 
reduced or delayed HIV-1 infection in NRG-hu Thy/HSC mice. 
After 4 weeks, HIV-1 replicated to similar levels in NRG-hu HSC 
and NRG-hu Thy/HSC mice. Furthermore, HIV-1 infection 
induced similar pathology including the depletion of human 
T cells and activation and exhaustion of T cells.
Combined antiretroviral therapy is able to suppress HIV-1 
replication but does not eradicate HIV-1 reservoir, which cause 
virus rebound after cART interruption. This lack of in vivo mod-
els of HIV-1 infection has hindered progress in finding a cure for 
HIV-1/AIDS. The use of both NRG-hu HSC and NRG-hu Thy/
HSC models of HIV-1 infection have made significant contribu-
tion to the field of HIV cure research (6, 7). We found here that 
both the HIV-1 infected NRG-hu HSC and NRG-hu Thy/HSC 
mice responded similarly to cART. Importantly, we found that 
type-I IFN signaling contributed to HIV-1 induced immune 
activation, dysfunction and fostered viral persistence in both 
NRG-hu HSC and NRG-hu Thy/HSC mice. Blockade of IFNAR 
reduced the level of T  cell activation, reversed T  cell exhaus-
tion, and reduced HIV-1 reservoirs in both models. Multiple 
mechanisms may lead to the reduction of HIV-1 reservoir size 
after IFNAR blockade. The rescued human T cells could target 
the HIV-1 reservoirs with elevated gene expression and clear 
the reservoir cells as we have reported (29, 30). Other factors, 
including HIV-1 induced death of reservoir cells, reduced general 
T cell activation after IFNAR blockade, may also contribute to the 
reduction of HIV-1 reservoir size (29).
Taken together, we conclude that both NRG-hu HSC and 
NRG-hu Thy/HSC mouse models are relevant and robust for the 
study of HIV-1 replication, pathogenesis and therapeutics. Each 
model has its own advantage and disadvantages. Compared 
with the NRG-hu Thy/HSC or Hu-BLT models, the advantages 
of the NRG-hu HSC model are as follows: (1) the procedure to 
construct NRG-hu HSC mice is simple, which only involving 
pre-irradiating the neonate immunodeficient mice followed by 
injecting human CD34+ HSCs (10, 11, 13). To generate NRG-hu 
Thy/HSC or Hu-BLT mice, a time consuming and technically dif-
ficult surgery procedure is needed to implant the human thymus 
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tissue under the kidney capsule of the mice (14, 15); (2) the 
source of HSCs to construct NRG-hu HSC mice is not restricted 
to fetal liver derived CD34+ cells. CD34+ HSCs from cord blood 
or human BM can also support the systemic development of 
human immune system (10, 14); (3) the graft-versus-host disease 
(GVHD) rarely happens in NRG-hu HSC mice, while the incident 
of GVHD is high in NRG-hu Thy/HSC or BLT mice (50) probably 
due to the mature human thymocytes in the transplanted thymic 
fragments; and (4) neonate immunodeficient mice are used to 
generate NRG-hu HSC mice, while 6- to 8-week-old mice are 
used for NRG-hu Thy/HSC or BLT mice construction. As the 
time needed for human immune reconstitution is 12–16 weeks 
in both models, researchers can start their experiments with 
younger NRG-hu HSC mice. The hu-Thy/HSC or BLT model also 
has its own advantages. It was reported that NOD-SCID-BLT (not 
NSG-BLT) mice supported better gut-associated lymphoid tissue 
development (GALT) (51). The other advantage of NRG-hu 
Thy/HSC or BLT model or hu-BLT model is that it supports the 
study of human HLA class I and class II restricted T cell response 
because human T cells develop in the presence of human thymic 
epithelium (14, 15, 40). However, as discussed earlier, human 
MHC-restricted T  cell response and therapies can be studied 
in NRG-hu HSC mice that transgenically express human HLA- 
genes (49).
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